Annual Report 2014 Delivering Growth

Total Page:16

File Type:pdf, Size:1020Kb

Annual Report 2014 Delivering Growth ANNUAL REPORT 2014 DELIVERING GROWTH MERCK GROUP → KEY FIGURES Change € million 2014 2013 in % Total revenues 11,500.8 11,095.1 3.7 Sales 11,291.5 10,700.1 5.5 Operating result (EBIT) 1,762.0 1,610.8 9.4 Margin (% of sales) 15.6 15.1 EBITDA 3,122.9 3,069.2 1.7 Margin (% of sales) 27.7 28.7 EBITDA pre one-time items 3,387.7 3,253.3 4.1 Margin (% of sales) 30.0 30.4 Earnings per share (€)1 2.66 2.77 –4.0 Earnings per share pre one-time items (€)1 4.60 4.39 4.8 Business free cash flow 2,605.1 2,960.0 –12.0 1 Taking into account the share split; previous year’s figures have been adjusted accordingly. See “Earnings per share” in the Notes to the Consolidated Financial Statements. MERCK GROUP → SALES € million 2014 → 11,291.5 2013 → 10,700.1 2012 → 10,740.8 2011 → 9,905.9 2010 → 8,928.9 MERCK GROUP → EBITDA PRE ONE-TIME ITEMS € million 2014 → 3,387.7 2013 → 3,253.3 2012 → 2,964.9 2011 → 2,723.8 2010 → 2,545.0 MERCK GROUP → Merck is a leading company for innovative and top-quality high- tech products in healthcare, life science and performance materials. Around 39,000 Merck employees work in 66 countries MERCK GROUP MERCK structure Company to improve the quality of life for patients, to foster the success → of customers and to help meet global challenges. MERCK GROUP → BUSINESS SECTORS AND BUSINESSES as of January 1, 2015 Merck Group Performance Healthcare Life Science Business sectors Materials Performance Merck Serono Merck Millipore Materials Businesses Consumer Health Allergopharma Biosimilars Effective January 1, 2015 Merck changed the structure of its financial reporting. As of the first quarter of 2015, the following three business sectors will be used for reporting purposes: → Healthcare comprises the Merck Serono, Consumer Health, Allergopharma and Biosimilars businesses. → Life Science refers to the business of Merck Millipore. → Performance Materials corresponds to the business of the same name. 208 mm ” WE ARE ALL PURSUING ONE GOAL: DELIVERING GROWTH WITH OUR IDEAS AND COMMITMENT TO OUR DAILY WORK. TO BENEFIT OUR PATIENTS, OUR CUSTOMERS, OUR SHAREHOLDERS AND OUR SOCIETY.” KARL-LUDWIG KLEY, Chairman of the Executive Board of Merck MERCK GROUP → HIGHLIGHTS of 2014 MAY 2 → ACQUISITION OF AZ ELECTRONIC MERCK GROUP GROUP MERCK Highlights 2014 ← MATERIALS Through the acquisition of AZ for around € 1.9 billion, 3 Merck expands its existing, highly profitable Liquid 2 Crystals business with high-tech electronic materials. AZ materials are widely used in integrated circuits, flat-panel displays and light-emitting diodes, making AZ an important partner to the MARCH 26 → leading global electronic manufacturers. MERCK ANNOUNCES FIT FOR 1 SHARE SPLIT 2018 Subsequent to a doubling in the value of Merck shares since the beginning of 2011, Merck announces a share split in a ratio of 1: 2. The share split became effective on June 30. 9 NOVEMBER 17 → 8 MERCK ENTERS INTO STRATEGIC ALLIANCE SEPTEMBER 30 → WITH PFIZER IN MERCK LAUNCHES IMMUNO-ONCOLOGY “PROUD TO BE Merck and Pfizer will jointly develop and commercialize a highly promising anti-PD-L1 antibody from the AN ORIGINAL” Merck research pipeline. In value terms, the transaction is the largest so far in the biopharmaceutical industry EMPLOYEE CAMPAIGN for a single asset at this stage of development. Immuno- oncology is about mobilizing the body’s own immune Merck kicks off a global communications campaign called system to fight tumor cells. “Proud to be an Original”. The campaign offers Merck’s 39,000 employees worldwide the opportunity to express their pride in working for Merck. AUGUST 1 → AUGUST 27 → NEW CFO MERCK BREAKS TAKES OFFICE GROUND AT A NEW Marcus Kuhnert joins Merck as Member of the PHARMACEUTICAL Executive Board and Chief Financial Officer. MANUFACTURING SITE IN CHINA Merck holds the groundbreaking ceremony 4 for its new pharmaceutical manufacturing site in Nantong, China. The new facility will be Merck’s second-largest worldwide. As of 2017, it will mainly focus on the bulk production and packaging of medicines referenced in China’s essential drug list. 5 SEPTEMBER 1 → GROUNDBREAKING CEREMONY FOR NEW GLOBAL 6 HEADQUARTERS The expansion of the Merck site in Darmstadt into a contemporary global headquarters is clearly taking shape. The symbolic groundbreaking officially marks the launch of the “ONE Global Headquarters” project. 7 SEPTEMBER 22 → SEPTEMBER 18 → MERCK ENTERS INTO MERCK ANNOUNCES AN AGREEMENT TO PLANS TO STRENGTHEN ACQUIRE SIGMA-ALDRICH THE EXECUTIVE BOARD Merck announces an agreement to acquire Sigma-Aldrich Effective January 1, 2015, Stefan Oschmann becomes for US$ 17.0 billion. The combination would establish Vice Chairman of the Executive Board. On the same date, one of the leading players in the US$ 130 billion global Belén Garijo becomes a Member of the Executive Board life science industry. On December 5, Sigma-Aldrich and assumes the leadership of the Healthcare business sector. share holders approve the merger with Merck. 208 mm 4 MAGAZINE → Table of contents The world is changing at breathtaking speed. Megatrends, which characterize the deep- seated social and technological changes taking place around the globe, are one reason. In this Annual Report, we take a closer look at four global trends. Our magazine shows how Merck is meeting them, positioning itself optimally for the future and taking decisive steps to help shape tomorrow. TREND/1 → TREND/2 → YOUNGER MARKETS FOR LONGER IN MOTION 6 – 11 12 – 17 While life expectancy is increasing, birth rates The middle class is growing – worldwide. As incomes are declining, even in many dynamic emerging rise, so do consumption and health awareness. countries. Merck is the global leader in fertility Merck sees these new markets as future hubs, and is treatment. becoming even more international. TREND/3 → TREND/4 → A CRYSTAL HEALTH FOR CLEAR FUTURE EVERYONE 18 – 25 26 – 31 The digital revolution is changing people’s lives For many people around the world, access to around the globe. With its expertise in liquid innovative health solutions is more of a dream crystals and insights into future trends, Merck, than a reality. In order to change this, Merck has the technology leader, is a key driver of future committed itself to numerous projects, for instance developments. in the fight against schistosomiasis. ANNUAL REPORT → Table of contents 5 TO OUR SHAREHOLDERS → CORPORATE GOVERNANCE → 32 – 41 142 –165 034 Letter from Karl-Ludwig Kley 144 Capital structure and governance bodies of Merck KGaA 038 The Executive Board 145 Statement on Corporate Governance 040 Merck Shares 162 Report of the Supervisory Board 164 Objectives of the Supervisory Board with respect to its composition GROUP MANAGEMENT CONSOLIDATED FINANCIAL REPORT → STATEMENTS → 42 –141 166 – 255 044 FUNDAMENTAL INFORMATION 168 Consolidated Income Statement ABOUT THE GROUP 169 Consolidated Statement of Comprehensive Income 044 The Merck Group 170 Consolidated Balance Sheet 050 Objectives and strategies of the Merck Group 171 Consolidated Cash Flow Statement 055 Internal management system of the Merck Group 172 Consolidated Statement of Changes in Net Equity 059 Corporate Responsibility 174 Notes to the Group accounts 067 Research and Development at Merck 077 Employees 256 RESPONSIBILITY STATEMENT 080 REPORT ON ECONOMIC POSITION 080 Macroeconomic and sector-specific environment 257 AUDITOR’S REPORT 082 Review of forecast against actual business developments 084 Course of business and economic position 258 Information and Service 084 Merck Group 097 Merck Serono 104 Consumer Health 109 Performance Materials 115 Merck Millipore 121 Corporate and Other 122 REPORT ON RISKS AND OPPORTUNITIES 134 REPORT ON EXPECTED DEVELOPMENTS 140 REPORT IN ACCORDANCE WITH SECTION 315 (4) OF THE GERMAN COMMERCIAL CODE (HGB) 141 SUBSEQUENT EVENTS → The full Consolidated Financial Statements can be found on our website at: ar2014.merckgroup.com TREND/1 → AGING POPULATIONS YOUNGER FOR LONGER “ What one has wished for in youth, in old age one has in abundance.” More and more people can relate to this quote from Johann Wolfgang von Goethe as life expectancies steadily increase worldwide. Birth rates, meanwhile, are sinking. These developments are reflected in the portfolio of products and services from Merck – including those that treat infertility and further cancer research. 8 MAGAZINE → Younger for longer FERTILITY → BIRTH RATES AND DISTRIBUTION Worldwide by region Fertility rate Northern Latin America America 7.0 and the Caribbean Birth 3.6 % distribution 7.6 % Europe Oceania 5.8 worldwide 5.4 % 2030 0.5 % 4.6 Asia Africa 3.4 50.7 % 32.2 % 2.2 1.0 1970 → 2030 On average, women are bearing fewer and fewer children. In Asia, the fertility rate is likely to decline significantly. Yet according to a forecast of the global distribution of births in 2030, Source: United Nations, World Fertility Patterns 2013 in absolute terms the majority of children will be born in Asia. “Catch me if you can!” yells Lovis as he “Congratulations, you’re pregnant!” The for in vitro fertilization is about 70 %. races across the playground. Little Henri elation over the birth of Lovis in February Hormone therapy is of decisive importance runs behind his older brother, shouting. 2008 was followed by another shock. The in treating infertility. As the world leader in The two boys keep their parents on their baby had cerebral hemorrhaging. “After a the fertility drug industry, Merck supplies toes. But for Silke (41) and Jens (44), difficult period, Lovis is a happy, normal hormones for each phase of the reproduc­ achieving this happy family was a long boy today,” the parents report with relief. tive cycle – from developing the egg cell to and difficult process. “At around the age And he now has a younger brother to play the early stage of pregnancy.
Recommended publications
  • R&D Update Call 2020
    R&D Update Call 2020 Luciano Rossetti, Global Head of Research & Development Rehan Verjee, Head of the Global Innovative Medicine Franchises & President of EMD Serono Joern-Peter Halle, Head of Research Klaus Edvardsen, Head of Oncology Development September 25, 2020 Disclaimer Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the group of companies affiliated with Merck KGaA, Darmstadt, Germany operates under individual business names (EMD Serono, Millipore Sigma, EMD Performance Materials). To reflect such fact and to avoid any misconceptions of the reader of the publication certain logos, terms and business descriptions of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada. 2 Disclaimer Cautionary Note Regarding Forward-Looking Statements and financial indicators This communication may include “forward-looking statements.” Statements that include words such as “anticipate,” “expect,” “should,” “would,” “intend,” “plan,” “project,” “seek,” “believe,” “will,” and other words of similar meaning in connection with future events or future operating or financial performance are often used to identify forward-looking statements. All statements in this communication, other than those relating to historical information or current conditions, are forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond control of Merck KGaA, Darmstadt, Germany, which could cause actual results to differ materially from such statements.
    [Show full text]
  • Certificate ISO 14001 From
    CERTIFICATE This is to certify that Merck KGaA Frankfurter Strasse 250 64293 Darmstadt Germany with the organizational units/sites as listed in the annex has implemented and maintains an Environmental Management System. Scope: Development, production and distribution of pharmaceuticals, chemical products and analytical systems. Through an audit, documented in a report, it was verified that the management system fulfills the requirements of the following standard: ISO 14001 : 2015 Certificate registration no. 005356 UM15 Valid from 2020-12-17 Valid until 2023-12-16 Date of certification 2020-11-18 DQS GmbH Markus Bleher Managing Director Accredited Body: DQS GmbH, August-Schanz-Straße 21, 60433 Frankfurt am Main, Germany 1 / 19 Annex to certificate Registration No. 005356 UM15 Merck KGaA Frankfurter Strasse 250 64293 Darmstadt Germany Location Scope 005356 Development, production and distribution of Merck KGaA pharmaceuticals, chemical products and Frankfurter Straße 250 analytical systems. 64293 Darmstadt Including: Real Estate GmbH Merck Performance Materials Germany GmbH Merck Healthcare KGaA With regional offices at: Roesslerstrasse 96 64293 Darmstadt Waldstrasse 3 64331 Weiterstadt 450237 Merck S.A. Production and distribution of pharmaceuticals Estrada dos Bandeirantes, 1099 and chemical products. Rio de Janeiro - RJ 22710-571 Brazil 450240 Merck Serono SA Production and distribution of Zone Industrielle de l´Ouriettaz pharmaceuticals. 1170 Aubonne Switzerland 450325 Merck Serono SA Development and production of Corsier-sur-Vevey pharmaceuticals. Rte de Fenil 25 1804 Fenil-sur-Vevey Switzerland This annex (edition: 2020-11-18) is only valid in connection with the above-mentioned certificate. 2 / 19 Annex to certificate Registration No. 005356 UM15 Merck KGaA Frankfurter Strasse 250 64293 Darmstadt Germany Location Scope 450241 Merck & Cie Production of chemical products.
    [Show full text]
  • Low Discontinuation Rate and Side-Effect Burden After Switching to Cladribine Tablets: Canadian Experience from the Advevatm Patient Support Program
    Low discontinuation rate and side-effect burden after switching to cladribine tablets: Canadian experience from the advevaTM patient support program Jiwon Oh1, Paul Giacomini2, Virginia Devonshire3, Fraser Clift4, Caroline Lemieux5, Meritxell Sabidó6, Arthur Allignol6, Mark S. Freedman7 1Division of Neurology, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, ON, Canada. 2Department of Neurology, Montreal Neurological Institute, McGill University, Montreal, QC, Canada. 3Division of Neurology, Department of Medicine, University of British Columbia MS/NMO Center, Vancouver, BC, Canada. 4Department of Neurology, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada. 5EMD Inc., Mississauga, Canada; a business of Merck KGaA, Darmstadt, Germany. 6Global Epidemiology Department, Merck KGaA, Darmstadt, Germany. 7Department of Medicine, Division of Neurology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada. ACTRIMS-ECTRIMS 2020 Virtual Congress | 11-13 September DISCLOSURES This study was sponsored by EMD Inc., Canada (a business of Merck KGaA, Darmstadt, Germany), who reviewed and provided feedback on the poster. The authors had full control of the poster, and provided their final approval of all content Jiwon Oh has received research support from Biogen-Idec, Roche, and EMD Serono and has received personal compensation for consulting from EMD Serono, Sanofi-Genzyme, Biogen-Idec, Roche, Celgene, and Novartis Paul Giacomini has received research or educational
    [Show full text]
  • Adding Cetuximab to Paclitaxel and Carboplatin for First-Line
    www.nature.com/bjc ARTICLE Clinical Study Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP Gunnar Folprecht1, Karolin Trautmann1, Alexander Stein2, Gerdt Huebner3, Michael Stahl4, Stefan Kasper5, Albrecht Kretzschmar6, Claus-Henning Köhne7, Viktor Grünwald 8,9, Ralf-Dieter Hofheinz10, Katharina Schütte1, Harald Löffler11, Carsten Bokemeyer2, Alwin Krämer12 and Arbeitsgemeinschaft Internistische Onkologie (AIO) - CUP Group BACKGROUND: Patients with carcinoma of unknown primary (CUP) have a dismal prognosis, even when treated with multi-agent chemotherapy. We hypothesised that adding the epidermal growth-factor receptor (EGFR) inhibitor cetuximab to standard first-line chemotherapy with paclitaxel and carboplatin would improve PFS and RR in unfavourable CUP. METHODS: This open-labelled, multicentre Phase 2 study included patients with unfavourable, untreated adeno- or undifferentiated CUP. Patients were randomised to receive either paclitaxel/carboplatin (group A) or paclitaxel/carboplatin plus cetuximab (group B) every 3 weeks for a maximum of 6 cycles followed by cetuximab maintenance in group B. The primary endpoint was PFS in the two groups. Secondary endpoints were RR, toxicity and overall survival (OS). RESULTS: One-hundred-and-fifty patients were randomised (group A = 72, group B = 78). The median PFS and OS for all patients were 3.8 and 8.1 months (95% confidence interval (CI): 2.9–4.8 and 6.8–9.5). There was no significant difference in PFS (3.7 vs 4.6 months, HR 0.98) or OS (8.1 vs 7.4, HR 1.1) between the two treatment groups.
    [Show full text]
  • Geschäftsbericht 2017
    350 Geschäftsbericht 2017 1668 Auszug aus dem „Apotheken-Privileg“ des Landesherren für den Unternehmensgründer FRIEDRICH JACOB MERCK: „ [Er soll die Apotheke] der ordnung gemeess mit guten frischen, zu ein= und anderen Curen dienlichen heil- samen Medicamentis und wahren also genugsamlich versehen, und damit fort und fort würklich continuiren, daß kein Mangel erscheine.“ 2018 STEFAN OSCHMANN Vorsitzender der Geschäftsleitung und CEO von Merck „ Wissenschaftliche Neu- gierde treibt uns seit 350 Jahren an. Durch sie wurden wir Techno logie- Pioniere. Und jetzt gestalten wir die digi tale Revolution mit.“ DIE ZUKUNFT SPRICHT SIMON CLARK sechs Jungforscherinnen und -forscher promoviert im Bereich Atmosphä- rische Physik an der University of Exeter. Auch in seinen YouTube- Videos geht es vor allem um physi- kalische Themen. „ Die Dinge verbessern sich nur, wenn es Leute gibt, die ver- rückte Ideen haben und etwas Neues ausprobieren.“ Treibt Merck frische Ideen voran? Die Antwort finden Sie auf Seite 10. SAMUEL CUNHA ist ein brasilianischer Parasitologe, der seine Leidenschaft für Biologie mit vielen Fans auf YouTube teilt. „ Um leidenschaftlich zu bleiben, muss man immer an die Zukunft denken, an das mögliche Ergebnis seiner Arbeit.“ Wie hält es Merck mit diesem Grundsatz? Die Antwort lesen Sie auf Seite 11. EVA AMSEN ist promovierte Biochemikerin, Autorin und Wissenschaftsvermittlerin in London. „ Für Wissen- schaftler ist es wichtig, dass sie sich nicht nur mit ihren Kollegen austauschen, sondern auch mit Menschen aus völlig anderen Bereichen – zum Bei- spiel mit Künstlern.“ Wird interdisziplinärer Austausch bei Merck gelebt? Die Antwort lesen Sie auf Seite 13. INÉS DAWSON ist promovierte Biologin in Oxford und beliebte YouTuberin. „ Forschung und Kreativität sollten Hand in Hand gehen, da nicht alle Probleme eine eindeutige Lösung haben.“ Fördert Merck Kreativität? Die Antwort finden Sie auf Seite 14.
    [Show full text]
  • Serono and Amgen Sign License Agreement for Multiple Sclerosis Product
    Serono And Amgen Sign License Agreement For Multiple Sclerosis Product November 13, 2002 FOR IMMEDIATE RELEASE THOUSAND OAKS, California, USA and GENEVA, SWITZERLAND - November 13, 2002 - Amgen Inc. (NASDAQ:AMGN) and Serono S.A. (virt-x: SEO and NYSE: SRA). Amgen and Serono announced today that they have signed a license and commercialization agreement by which Serono will sell the marketed drug Novantrone® (mitoxantrone for injection concentrate) in the United States. Novantrone is approved by the FDA in the United States for secondary progressive, progressive relapsing and worsening relapsing-remitting multiple sclerosis, as well as for certain forms of cancer in the United States. The terms were undisclosed. Novantrone was acquired by Amgen in connection with Amgen's acquisition of Immunex Corporation in July 2002. The drug was approved by the FDA for MS indications in October, 2000, and had U.S. sales of $71 million last year. It has also been approved for certain oncology indications since 1987. Full prescribing information for Novantrone can be obtained by visiting www.novantrone.com. Closing of the transaction is subject to review and clearance by U.S. regulatory authorities. Amgen is a global biotechnology company that discovers, develops, manufactures and markets important human therapeutics based on advances in cellular and molecular biology. Serono is a global biotechnology leader with six recombinant products on the market, Gonal-F®, Luveris®, Ovidrel®/Ovitrelle®, Rebif®, Serostim® and Saizen® (somatropin). (Luveris® is not approved in the USA). This news release contains forward-looking statements that involve significant risks and uncertainties, including the possibility that the license transaction will not close or that the companies may be required to modify aspects of the transaction to achieve regulatory approval, and other risks and uncertainties including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent Form 10-Q.
    [Show full text]
  • Rationale and Design of Classic-MS Study
    Rationale and Design of Classic-MS METHODS Study Evaluating Long-Term Efficacy for • Following pre-baseline screening and assessment for eligibility, long-term Table 2. CLASSIC-MS Schedule of Data Collection Patients with Multiple Sclerosis Treated retrospective data will be obtained from medical records at Study Visit 1; prospective data will be collected at Study Visits 1 and 2. Assessments & Procedures Screening Study Visit 1* Study Visit 2† with Cladribine Tablets • Patients will be enrolled during 17 months between Q3 2019–Q4 2020. Informed consent X • The last Patient Last Visit is expected in Q1 2021. 1 2 3 4 5 6,7 8 9 A. Boyko , J. Correale , G. Edan , M.S. Freedman , G. Giovannoni , X. Montalban , K. Rammohan , T. Leist , Inclusion and exclusion 10 11 12 13 12 GET POSTER PDF X D. Stefoski ,B. Yamout , B. Garcia-Alonso , A. Aydemir , E. Verdun Di Cantogno , on behalf of the CLASSIC-MS Copies of this poster obtained criteria Study Group through QR (Quick Response) code Figure 1. CLASSIC-MS Study Visit and Data Collection Sociodemographic and are for personal use only and may X clinical characteristics 1Pirogov Russian National Research Medical University, Moscow, Russia; 2FLENI Institute, Buenos Aires, Argentina; 3Department of not be reproduced without written 4 permission of the authors Neurology, University Hospital of Rennes, France; University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Key: Prospective Data Collection Canada; 5Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; 6Division of Neurology, St Michael’s Hospital, University of Toronto, Toronto, ON, Canada; 7Department of Neurology-Neuroimmunology, Prospective data collected atas StudyStudy VisiVisitt Physical examination X 8 Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Barcelona, Spain; University of Miami School Retrospective data obtained from medical chart review and/or in-house study databases.
    [Show full text]
  • Expert Opinion on the Use of Cladribine Tablets in Clinical Practice
    Expert Opinion on the Use of Cladribine METHODS • The consensus program was based on a multi-step modified Delphi • A comprehensive literature review was performed for each question. The Tablets in Clinical Practice methodology, which took place between April 2018 and April 2019. level of evidence was assessed and agreed by the SC.4 • A Steering Committee (SC) of nine international MS experts led the program. • A questionnaire was developed by the SC with draft answers based on The SC in turn was supported by an extended faculty (EF, n=33) of practicing available evidence from the literature review, combined with their expert P. Soelberg Sørensen1, D. Centonze2, G. Giovannoni3, X. Montalban4,5, D. Selchen5, P. Vermersch6, H. Wiendl7, B. Yamout8, neurologists caring for MS patients. A total of 19 countries were represented opinion, where evidence was lacking. The questionnaire was completed H. Salloukh9, P. Rieckmann10 in the program. The role of the EF was to review available evidence, remotely via an on-line platform by the EF. complete a questionnaire and finally vote on draft recommendations. 1Danish Multiple Sclerosis Center, Department of Neurology, University of Copenhagen and Rigshospitalet, Copenhagen, Denmark; 2Unit of GET POSTER PDF • The results from the questionnaire were incorporated into draft clinical Neurology and Neurorehabilitation, IRCCS Neuromed, Pozzilli (IS), Italy; 3Blizard Institute, Barts and The London School of Medicine and Dentistry, Copies of this poster obtained • The SC identified practical clinical questions concerning the use of cladribine recommendations, which were then voted on by the SC and EF members. 4 Queen Mary University of London, London, UK; Department of Neurology, Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall through QR (Quick Response) tablets and prioritized the most important 11 questions to be addressed, d’Hebron University Hospital, Barcelona, Spain; 5University of Toronto, Division of Neurology, St.
    [Show full text]
  • Merck Serono the Biopharma Division of Merck
    Merck Serono The Biopharma Division of Merck September 16, 2014 Merck Our aspiration is to make great things happen Merck is the oldest pharmaceutical and chemical company in the world founded in 1668 in Darmstadt, Germany Merck is a publicly listed company on the DAX at the Frankfurt Stock exchange. The Merck family holds 70% of the shares Total Revenues : €11 billion in 2013 EBITDA Pre : €3.25 billion Around 38,000 employees in 66 countries 2 Our History Merck was founded by Friedrich Jacob Merck (1621-1678) when he acquired the Angel Pharmacy (Engel-Apotheke) in 1668 Heinrich Emanuel Merck (1794–1855) begins production on an industrial scale Merck and the US pharmaceutical company Merck, Sharp & Dohme have been two independent companies since 1917. Today, we are Merck worldwide (except for Canada and the US where we are known as EMD). 3 Our Corporate Structure Merck Group Merck Consumer Performance Merck Serono Health Materials Millipore • Oncology • Everyday health • Liquid Crystals • BioScience • ImmunoOncology protection • Pigments • Lab Solutions • Immunology/NDD • Women‘s and & Cosmetics • Process Solutions • Fertility children‘s health • Endocrinology & • Cough and cold General Medicine Biosimilars Allergopharma Pharma Business Merck Serono at a Glance We operate under the Group: Largest division of Merck name EMD Serono in Established: January 5, 2007 North America Business: Biopharmaceuticals Employees: ~15,000 Total Revenues: €6.3 billion in 2013 Headquarters: Darmstadt, Germany Global reach: Products commercialized in 150
    [Show full text]
  • Mitoxantrone in Multiple Sclerosis: 1- MEDLINE and 2- Cochrane Library
    SHOULD THE MUHC USE MITOXANTRONE IN THE TREATMENT OF MULTIPLE SCLEROSIS? A Technology Assessment By The Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC) Dec 2, 2002. 1 This analysis was prepared for the Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC) by Chantal Bourgault PhD, Medical Scientist of the TAU. and Maurice McGregor MD, Cardiology Division, MUHC. and approved and adopted by the committee of the TAU: J. Barkun, W. Brodie, J. Brophy, J. Johnston, M. Kaplow, J. MacPhail, G. Pekeles, R. Rajan, J. Ritchie, F. Salevsky, S. Suissa, M. McGregor. With the additional members: J. Antel, D.Arnold, A.Bar-Or, J.Chambers-Evans, Y.Lapierre and A. Lynch. Acknowledgments The expert assistance of the following individuals is gratefully acknowledged: Consultants: Yves Lapierre MD. Head, Multiple Sclerosis Clinic, Montreal Neurological Hospital of the MUHC. John Penrod PhD. Centre for the Analysis of Cost Effective Care, MUHC. Reviewers: Jack Antel MD. Coordinator, MS Programme, Montreal Neurological Institute, MUHC. Amit Bar-Or MD. Neurologist, MS Clinic, Montreal Neurological Institute, MUHC. Douglas Arnold MD. Neurologist, MS Clinic, Montreal Neurological Institute, MUHC. J. Chambers-Evans. Chair, Adult Clinic Ethics Committee, MUHC. Information Sources: Ms Linda Maruska. Department of Quality Management, MUHC. (Cost Data) Mr Gilles Gaudet. Department of Finance, MUHC. (Cost Data). Mr Andre Bonnici. Coordinator, Pharmacy and Therapeutics Ctee, MUHC.(Cost Data). Ms Diane Lowden. Clinical Nurse Specialist, MS. Programme. (MS Clinic Data). 2 Invitation. This document was designed to assist decision-making in the McGill University Health Centre. Others are welcome to make use of it, preferably with acknowledgment.
    [Show full text]
  • 'No Free Lunch'
    11-12/2013 December Markets and Companies Information Technology The Middle East and China THE NEWSPAPER FOR THE Adaptability is more important are catching up to the than ever as the fourth industrial chemical-producing West. CHEMICAL AND revolution takes off. Page 5 LIFE SCIENCE MARKETS Page 9 N EWSFLOW Markets and Companies: ‘No Free Lunch’ Merck KGaA offers £1.6 billion for AZ Materials. Bjørn Lomborg on the Give and Take in Greenhouse Gas Reduction Allessa to cut a third of its work- force. New Thinking – Bjørn Lomborg plants over a 10-year period, be- tray the fact that there is no sense might not be a household name in DuPont says it will spin off its Per- of economic reality. We are not the chemical industry, but the mention formance Chemicals unit. going to cut carbon emissions sig- of his name in environmental activist nificantly, as long as it is very, very costly.” EU Commissioner demands unified circles seems to provoke one of two framework for shale gas in Europe. reactions: adoration or distain. Lom- Lomborg On The Energy Transition borg, a Danish academic who rose to China is looking for new targets for The 2011 Fukushima disaster its abundant fuel. notoriety in 2001 with his controversial rocked many countries using nu- book “The Skeptical Environmentalist,” clear power to the core; it seemed Dow gears up to sell its Chlor-Alkali that no one was more chilled than can be found on a handful of top 50 or and Epoxy units. German Chancellor Angela Merkel top 100 lists for the world’s top intel- and her reigning party of Christian More on Pages 2-8 ▶ Democrats.
    [Show full text]
  • MERCK Kgaa DARMSTADT, GERMANY
    MERCK KGaA DARMSTADT, GERMANY Annual Financial Statements 2016 DISCLAIMER Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany, operate as EMD Serono in Healthcare, MilliporeSig- ma in Life Science and EMD Performance Materials. To reflect such fact and to avoid any misconception of the reader of the publication certain logos, terms and names of businesses of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada. For nearly 350 years, curious people at our company have been bringing ideas to life. As a global science and technology company, a passion for research and discovery is our most valuable resource. With our three business sectors, namely Healthcare, Life Science and Performance Materials, we improve the quality of life of patients, in- crease the success of our customers, and offer solutions for diverse challenges. Curiosity is and remains our strongest driving force for future-oriented innovations. Annual Financial Statements 3 Combined Management Annual Financial Statements Report 112 – 158 03 – 110 112 Balance Sheet as of December 31, 2016 113 Income Statement from the period 003 Fundamental Information about the Group from January 1 to December 31, 2016 003 The Group 114 Notes to the Annual Financial Statements 010 Objectives and strategies 115 Notes to the Balance Sheet 016 Internal Management System 125 Notes to the Income Statement 020 Corporate Responsibility 129 Other Disclosures 028 Research and development 132 Members of the Executive Board of Merck KGaA, 040 People Darmstadt, Germany 133 Supervisory Board 046 Report on Economic Position 134 Disclosures in accordance with section 160 (1) no.
    [Show full text]